A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis (NIBIT-M2)

Clinical Trial ID NCT02460068

Rank	Title	Journal	Year	PubWeight™‹?›
1	Nivolumab plus ipilimumab in advanced melanoma.	N Engl J Med	2013	17.53
2	Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.	Lancet Oncol	2012	5.32
3	Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.	J Clin Oncol	2004	3.97
4	Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.	Lancet Oncol	2012	2.03
5	Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study.	Ann Oncol	2014	0.91
6	Updates in the management of brain metastases.	Neuro Oncol	2016	0.88
7	Systemic Immunotherapy for the Treatment of Brain Metastases.	Front Oncol	2016	0.82
8	Embracing rejection: Immunologic trends in brain metastasis.	Oncoimmunology	2016	0.75
9	Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management.	Hum Vaccin Immunother	2016	0.75
10	Melanoma Brain Metastasis: Mechanisms, Models, and Medicine.	Int J Mol Sci	2016	0.75